Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism CD39 inhibitors(Ectonucleoside triphosphate diphosphohydrolase 1 inhibitors), CD73 inhibitors(5'-nucleotidase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | IND Approval | CN | 08 Jul 2024 |